Kengreal

(Cangrelor)

ApprovedSmall molecule

Cangrelor is used to prevent blood clots in patients undergoing heart catheterization procedures, particularly in those at high risk for clot formation during the procedure.[2] Kengreal is currently approved and in use across 12 indications[4].[1]

Kengreal is one of 248 small molecule programs targeting Cardiac Arrest. It is currently in Approved.

Indications

Total Trials

Active Trials

247

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Cardiac ArrestActive, not recruiting

Thrombotic DiseaseActive, not recruiting

Recurrent ThrombophlebitisActive, not recruiting

IschemiaApproved

Coronary Artery DiseaseCompleted

ST Elevation Myocardial InfarctionApproved

Acute Coronary SyndromeApproved

Acute Myocardial InfarctionCompleted

Myocardial InfarctionTerminated

StrokeRecruiting

Cardiac ArrestApproved

Active, not recruiting

Thrombotic DiseaseApproved

Active, not recruiting

Recurrent ThrombophlebitisApproved

Active, not recruiting

IschemiaApproved

Approved

Coronary Artery DiseaseApproved

Completed

ST Elevation Myocardial InfarctionApproved

Approved

Acute Coronary SyndromeApproved

Approved

Acute Myocardial InfarctionApproved

Completed

Myocardial InfarctionApproved

Terminated

StrokePhase 3

Recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

150 competitors in Stroke

#DrugCompanyPhaseTrials

Kengreal

Chiesi Farmaceutici S.p.A.

Approved

1 2

Zometa

Pfizer

Preclinical

1 3

Savella

AbbVie

Preclinical

1 4

Proamatine

Repatha

Zantac 150

1 7

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Alka-Seltzer

AAbbott

Preclinical

1 9

Haldol

DDePuy Orthopaedics

Preclinical

1 10

Anticoagulants

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Percutaneous Coronary Intervention

NCT06089577

Q4 2027

Post-ApprovalNot yet recruiting

Antiplatelet Therapy

NCT07225842

Q3 2030

Phase 3Recruiting

Stroke

NCT04667078

Clinical

Trials by Indication[1]

Percutaneous Coronary Intervention3 trials

Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention

Terminated·IInova Health Care Services··NCT03048019·10 enrolled

Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention

Recruiting·FFederico II University·Phase 4·NCT06089577·80 enrolled

Intravenous CAngrelor in High-bleeding Risk Patients Undergoing percutaneouS Coronary Intervention (ICARUS) Registry

Unknown status·UUniversita degli Studi di Genova··NCT05505591·900 enrolled

Platelet Inhibition3 trials

Maintenance of Platelet Inhibition With Cangrelor

Completed· Novartis logo

Novartis·Phase 2·NCT00767507·221 enrolled

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Terminated· Novartis logo

Novartis·Phase 3·NCT00385138·5,364 enrolled

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI

Completed·UUniversity of Florida·Phase 4·NCT03247738·50 enrolled

Myocardial Infarction2 trials

Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size

Terminated·—·Phase 4·NCT03043274·23 enrolled

Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO

Recruiting·IIRCCS San Raffaele·Phase 2·NCT06792643·50 enrolled

Antiplatelet Therapy2 trials

Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery (MONET BRIDGE)

Unknown status·OOspedale Santa Croce-Carle Cuneo·Phase 2·NCT03862651·140 enrolled

The Bridging Antiplatelet Therapy With Cangrelor 2 Study

Not yet recruiting·UUniversity of Florida·Phase 4·NCT07225842·50 enrolled

GIST2 trials

Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry)

Completed·FFederico II University··NCT04790032·150 enrolled

Dutch Cangrelor Registry

Completed·IIsala··NCT04138641·250 enrolled

15 more indications

Oral1 trial

The Effect of IV Cangrelor and Oral Ticagrelor Study

Completed·TThe Royal Wolverhampton Hospitals NHS Trust·Phase 4·NCT02733341·100 enrolled

PK/PD1 trial

Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor

Completed· Novartis logo

Novartis·Phase 1·NCT00102674·40 enrolled

Injury1 trial

Platelet Inhibition to Target Reperfusion Injury

Unknown status·NNational Heart Centre Singapore·Phase 2·NCT03102723·228 enrolled

Randomized1 trial

Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.

Completed·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT02978040·122 enrolled

Acute Myocardial Infarction1 trial

Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction

Completed·FFaculty Hospital Kralovske Vinohrady·Phase 4·NCT03551964·605 enrolled

Treatment1 trial

PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment

Completed·UUniversity of Florida·Phase 4·NCT04634162·22 enrolled

ESS1 trial

Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers

Completed· Novartis logo

Novartis·Phase 1·NCT00699504·67 enrolled

Cardiac Arrest1 trial

Add-on Cangrelor in STEMI-triggered Cardiac Arrest

Unknown status·MMedical University of Vienna·Phase 4·NCT03273075·60 enrolled

Clinical Trial1 trial

A Clinical Trial to Demonstrate the Efficacy of Cangrelor

Terminated· Novartis logo

Novartis·Phase 3·NCT00305162·8,882 enrolled

Coma1 trial

Cangrelor in Comatose Survivors of OHCA Undergoing Primary PCI

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT04005729·30 enrolled

Neonatal1 trial

Cangrelor Neonatal PK/PD and Safety Study

Completed· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 1·NCT02765633·22 enrolled

Stroke1 trial

REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts

Recruiting·FFondation Ophtalmologique Adolphe de Rothschild·Phase 3·NCT04667078·368 enrolled

Clopidogrel1 trial

Cangrelor to Clopidogrel or Prasugrel Transition Study

Completed· Novartis logo

Novartis·Phase 2·NCT01979445·15 enrolled

Itching1 trial

Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI

Completed·UUniversity of Florida·Phase 4·NCT04668144·359 enrolled

Unspecified2 trials

Cangrelor Prasugrel Transition Study

Completed· Novartis logo

Novartis·Phase 2·NCT01852019·12 enrolled

Cangrelor Ticagrelor Transition Study

Completed· Novartis logo

Novartis·Phase 2·NCT01766466·12 enrolled

Regulatory

FDA Approval Timeline[5]

Jun 22, 2015

KENGREAL

NDA NDA204958

Mar 2, 2016

KENGREAL

NDA NDA204958

Oct 23, 2019

KENGREAL

NDA NDA204958

Jan 26, 2023

KENGREAL

NDA NDA204958

Sources

References

[1]
ClinicalTrials.gov — 28 trial records for Cangrelor. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Kengreal drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Cangrelor compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Cangrelor. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA204958). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Kengreal. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Chiesi Farmaceutici S.p.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Purinergic Receptor P2Y12 Antagonist; Purinergic Receptor P2Y12 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Chiesi Farmaceutici S.p.A.

Patent Landscape[6]

Patent Cliff

May 13, 2029

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9925265May 13, 2029

9427448Nov 10, 2030

8680052Mar 9, 2033

10039780Jul 10, 2035

9439921Jul 10, 2035

2 more patents

9700575Jul 10, 2035

9295687Jul 10, 2035

Kengreal

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q3 2030

Trials by Indication[1]

Percutaneous Coronary Intervention3 trials

Platelet Inhibition3 trials

Myocardial Infarction2 trials

Antiplatelet Therapy2 trials

GIST2 trials

Oral1 trial

PK/PD1 trial

Injury1 trial

Randomized1 trial

Acute Myocardial Infarction1 trial

Treatment1 trial

ESS1 trial

Cardiac Arrest1 trial

Clinical Trial1 trial

Coma1 trial

Neonatal1 trial

Stroke1 trial

Clopidogrel1 trial

Itching1 trial

Unspecified2 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News